The microorganisms that collectively form the human skin are also known as microbiomes. Skin diseases are sometimes are nothing but the imbalance of microbiomes. The Human Microbiome Project highlighted that coevolution of the host-microbiome superorganism and the unperturbed microbial component of the dyad can help render sustainable host health. The program was launched in phases, and the second phase highlighted on procurement of a complete profile of the human microbiome. It focuses on understanding the presence of the microbiota in a diseased and healthy state of the human body.
This is indicated recently when Micreos Human Health, a Dutch biotech company, initiated clinical trials to evaluate the world's first endolysin-drug for Atopic Dermatitis treatment. This study highlights the world's first evaluation of a pharmaceutical endolysin for topical use in humans.
Another study by the National Institutes of Health study highlights that, in an experiment modification, the skin microbiome has safely reduced the severity of the Eczema disease in children as young as three years of age.
Based on another study on skin microbiota–host interactions, it was established that a balanced skin microbiome includes a healthy host and a balanced host population. This contains an ample amount of good bacteria, which safeguard and prevent other pathogenic bacteria from spreading excessively.
According to the market intelligence published by BIS Research, the global skin microbiome modulators market was estimated at $541.1 million in 2019. The market is projected to grow at a CAGR of 16.90% during the forecast period from 2020 to 2030.
The growth is accredited to market drivers such as the increasing emphasis on microbiome’s potential for human health, the increasing entry of legacy cosmetic companies into skin microbiome modulators industry, and the decreasing cost of sequencing. All the three factors are expected to have a strong influence on the growth of the market.
Currently, the microbiome research and commercialization are still at a nascent stage. However, several eminent companies of the healthcare industry are showcasing increasing inclination toward the human microbiome technology. Over the years, prominent pharmaceutical companies have entered the human microbiome market with the help of different strategies. Among the top 50 pharmaceutical companies in the world, almost 35 companies have explicitly expressed interest in microbiome research.
For instance, Royal DSM formed an alliance with Metex, a French biochemical specialist, to deliver a cosmetic-grade 1.3 propanediol (PDO) ingredient, bio-sourced from non-GMO feedstocks. The company is now commercializing it and has procured a microbiome-friendly certification for the ingredient.
Moreover, the research on the microbiome has offered the world with not only several new insights but also advanced technologies that can be harnessed to accentuate the potential of this discipline. However, the research on discovering the potential benefits of skin microbiome still continues. Several consortiums have been formed for promoting the increased collaboration among companies at a global level. The advent of live probiotic and prebiotic ingredients in active cosmetics has revolutionized the skincare industry.
